Gilad Yosi, Firer Michael, Gellerman Gary
Department of Chemical Sciences, Ariel University, Ariel 40700, Israel.
Department of Chemical Engineering and Biotechnology, Ariel University, Ariel 40700, Israel.
Biomedicines. 2016 May 26;4(2):11. doi: 10.3390/biomedicines4020011.
Targeted delivery of chemotherapeutics and diagnostic agents conjugated to carrier ligands has made significant progress in recent years, both in regards to the structural design of the conjugates and their biological effectiveness. The goal of targeting specific cell surface receptors through structural compatibility has encouraged the use of peptides as highly specific carriers as short peptides are usually non-antigenic, are structurally simple and synthetically diverse. Recent years have seen many developments in the field of peptide based drug conjugates (PDCs), particularly for cancer therapy, as their use aims to bypass off-target side-effects, reducing the morbidity common to conventional chemotherapy. However, no PDCs have as yet obtained regulatory approval. In this review, we describe the evolution of the peptide-based strategy for targeted delivery of chemotherapeutics and discuss recent innovations in the arena that should lead in the near future to their clinical application.
近年来，与载体配体偶联的化疗药物和诊断剂的靶向递送在偶联物的结构设计及其生物学有效性方面都取得了重大进展。通过结构兼容性靶向特定细胞表面受体的目标，促使人们使用肽作为高度特异性的载体，因为短肽通常无抗原性，结构简单且合成多样。近年来，基于肽的药物偶联物（PDC）领域有了许多进展，特别是在癌症治疗方面，因为其使用旨在避免脱靶副作用，降低传统化疗常见的发病率。然而，目前尚无PDC获得监管批准。在本综述中，我们描述了基于肽的化疗药物靶向递送策略的演变，并讨论了该领域的最新创新，这些创新有望在不久的将来引领其临床应用。
